3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Carcinoma, Transitional Cell
4
Urinary Bladder Neoplasms
3
Ureteral Neoplasms
2
Neoplasm Metastasis
2
Lung Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Breast Neoplasms
2
Urologic Neoplasms
1
Urogenital Neoplasms
1
Urethral Neoplasms
1
Renal Insufficiency
1
Recurrence
1
Prostatic Neoplasms
1
Penile Neoplasms
1
Neoplasms
1
Kidney Neoplasms
1
Carcinoma, Small Cell
1
Carcinoma
1
Breast Neoplasms, Male
1
Interventions
Gemcitabine
6
Trastuzumab
4
Carboplatin
3
pembrolizumab
2
Pemetrexed
2
Paclitaxel
2
Cisplatin
2
vinflunine
1
tucatinib
1
relatlimab
1
palbociclib
1
niraparib
1
motexafin gadolinium
1
montanide ISA 51
1
flt3 ligand protein
1
enfortumab vedotin
1
cabozantinib
1
atezolizumab
1
apatorsen
1
abemaciclib
1
Zoledronic Acid
1
Urinary Diversion
1
Therapeutics
1
Thalidomide
1
Sunitinib
1
Radiosurgery
1
Nivolumab
1
Mitomycin
1
MART-1 Antigen
1
Immunoglobulins, Intravenous
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Urologic Neoplasms
×
vinflunine
×
Clear all
NCT01599013
2015-12-08
JASINT1
Pierre Fabre Medicament
Phase 2
Completed
69 enrolled